Antibody Drug Conjugates Market Scope And Analysis

  • Report Code : TIPRE00003494
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 293
Buy Now

Antibody Drug Conjugates Market Analysis, Scope, and Growth by 2030

Buy Now

Antibody Drug Conjugates Market Report Antibody Drug Conjugates Market Size and Share Antibody Drug Conjugates Market Scope and Analysis

Antibody Drug Conjugates Market Report Scope

Report Attribute Details
Market size in 2023 US$ 8,105.65 Million
Market Size by 2031 US$ 38,077.45 Million
Global CAGR (2023 - 2031) 21.3%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Technology
  • Cleavable Linker
  • Non-cleavable Linker
By Application
  • Blood Cancer
  • Brain Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
By Target
  • HER2
  • CD22
  • CD30
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • ADC Therapeutics SA
  • Pfizer Inc
  • F Hoffmann La Roche Ltd
  • Daiichi Sankyo Co Ltd
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd

    • Antibody Drug Conjugates Market News and Recent Developments

    The antibody drug conjugates market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are listed below:

    • AstraZeneca constructed a manufacturing facility dedicated to antibody drug conjugates in Singapore. Valued at US$ 1.5 billion, the facility will work to improve the global supply of its antibody drug conjugates portfolio. Antibody drug conjugates are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies. (Source: AstraZeneca, Company Website, November 2024).
    • Daiichi Sankyo and AstraZeneca received conditional approval for ENHERTU (trastuzumab deruxtecan) in China. This treatment is indicated for adult patients with unresectable, locally advanced, or metastatic NSCLC that have HER2 (ERBB2) mutations and have received prior systemic therapy. Full approval will depend on the results of a confirmatory trial. (Source: Daiichi Sankyo, Company Website, October 2024)

    Antibody Drug Conjugates Market Report Coverage and Deliverables

    The "Antibody Drug Conjugates Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

    • Antibody drug conjugates market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Antibody drug conjugates market trends, as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Antibody drug conjugates market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the antibody drug conjugates market
    • Detailed company profiles